

(12) United States Patent Ghosh

US 10,000,505 B2 (10) **Patent No.:**

(45) Date of Patent: Jun. 19, 2018

(54) ANTI-CANCER AGENTS AND PREPARATION THEREOF

(71) Applicant: Purdue Research Foundation, West

Lafayette, IN (US)

(72)Inventor: Arun K. Ghosh, West Lafayette, IN

Assignee: Purdue Research Foundation, West

Lafayette, IN (US)

(*) Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. days.

(21) Appl. No.: 15/038,027

(22) PCT Filed: Nov. 19, 2014

(86) PCT No.: PCT/US2014/066458

§ 371 (c)(1),

(2) Date: May 19, 2016

(87) PCT Pub. No.: WO2015/077370

PCT Pub. Date: May 28, 2015

(65)**Prior Publication Data**

US 2016/0297831 A1 Oct. 13, 2016

Related U.S. Application Data

- (60) Provisional application No. 61/906,133, filed on Nov. 19, 2013.
- (51) Int. Cl. A61K 31/336 (2006.01)A61K 31/35 (2006.01)A61K 31/495 (2006.01)A61K 31/535 (2006.01)C07D 493/10 (2006.01)C07D 407/12 (2006.01)A61K 31/5377 (2006.01)A61K 45/06 (2006.01)C07D 309/14 (2006.01)A61K 47/68 (2017.01)

(52) U.S. Cl.

CPC C07D 493/10 (2013.01); A61K 31/336 (2013.01); A61K 31/35 (2013.01); A61K 31/495 (2013.01); A61K 31/535 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); A61K 47/6803 (2017.08); C07D 309/14 (2013.01); C07D 407/12 (2013.01)

(58) Field of Classification Search

CPC C07D 493/10; A61K 31/336; A61K 31/35; A61K 31/495; A61K 31/535

See application file for complete search history.

(56)References Cited

U.S. PATENT DOCUMENTS

7,825,267 B2 * 11/2010 Koide C07D 303/12 549/332 8,309,599 B2 11/2012 Koide et al.

2011/0207604 A1 8/2011 Asolkar et al.

FOREIGN PATENT DOCUMENTS

CN	105829299 A	8/2016
IN	201617020519 A	8/2016
JP	2017503753 A	2/2017
WO	WO-2013032693 A2	3/2013
WO	WO-2014068443 A1	5/2014
WO	WO-2015077370 A1	5/2015

OTHER PUBLICATIONS

"International Application Serial No. PCT/US2014/066458, International Search Report dated Feb. 4, 2015", 3 pgs.

"International Application Serial No. PCT/US2014/066458, Written

Opinion dated Feb. 4, 2015", 5 pgs. Ghosh, et al., "?Enantfoselective Syntheses of FR901464 arid SpliceostatIn A: Potent Inhibitors of Spliceosome?", Ord. Lett. 15 (19), (Sep. 19, 2013), 5088?5091.

Horigome, "A synthesis of FR901464", Tetrahedron Letters 42, (2001), 8207-8210.

Koide, et al., "Total Syntheses of FR901464", Review Article, [Online] retrieved from the Internet: https://www.jstage.jst.go.jp/ article/yuklgoselkyokalshi1943/65/2/65_2_119/___pdf, (2007), p.

Motoyoshi, "Total synthesis of FR901464: second generation", Tetrahedron 62, (200), 1378-1389.

"Colombian Application Serial No. 16-160.200, Office Action dated Nov. 8, 2016", 2 pgs.

"Colombian Application Serial No. 16-160.200, Response Filed Mar. 8, 2017 to Office Action dated Nov. 8, 2016", (W/ Translated Claims), 11 pgs.

"European Application Serial No. 14863201.1, Supplementary Partial European Search Report dated Apr. 6, 2017", 8 pgs.

"International Application Serial No. PCT/US2014/066458, International Preliminary Report on Patentability dated Jun. 2, 2016", 7

pgs.
"Vietnam Application Serial No. 1-2016-02239, Response filed Jan. 6, 2017 to Office Action dated Oct. 6, 2016".

Ghosh, Arun K, et al., "Enantioselective Syntheses of FR901464 and Spliceostatin A: Potent Inhibitors of Spliceosome", Organic Letters, 14(23), (Oct. 4, 2013), 5088-5091 pgs.

Osman, Sami, et al., "Structural Requirements for the Antiproliferative Activity of Pre-mRNA Splicing Inhibitor FR901464", Chemistry—A European Journal, vol. 17, No. 3, (Nov. 19, 2010), 895-904

pgs.
"Eurasian Application Serial No. 201691010, Office Action dated
"Eurasian Application Serial No. 201691010, Office Action dated Jun. 7, 2017", W/ English Translation, 6 pgs (partial translation). "European Application Serial No. 14863201.1, Extended European Search Report dated Aug. 4, 2017", 11 pgs.

* cited by examiner

Primary Examiner — Yong S. Chong (74) Attorney, Agent, or Firm — Schwegman Lundberg & Woessner, P.A.

ABSTRACT

Embodiments of the present invention provide, among other compounds, a family of spliceosome-inhibiting compounds that can be used as therapeutic anti-cancer agents. The compounds are synthesized in a process that includes the catalytic cross metathesis of a cyclic epoxy alcohol to an amide.

9 Claims, No Drawings